Second primary malignancies after commercial CAR T-cell therapy: Analysis of the FDA Adverse Events Reporting System Research Letter

  

Authors:	Elsallab, M.; Ellithi, M.; Lunning, M. A.; D'Angelo, C.; Ma, J.; Perales, M. A.; Frigault, M.; Maus, M. V.
Title:	Second primary malignancies after commercial CAR T-cell therapy: Analysis of the FDA Adverse Events Reporting System
Abstract:	Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports following chimeric antigen receptor T-cell therapies in the Food and Drug Administration Adverse Event Reporting System. Myeloid and T-cell neoplasms were disproportionately more frequently reported, warranting further follow-up. © 2024 American Society of Hematology
Keywords:	adult; treatment outcome; aged; middle aged; leukemia; bone tumor; united states; united states food and drug administration; follow up; melanoma; mantle cell lymphoma; multiple myeloma; incidence; food and drug administration; hodgkin disease; risk assessment; skin tumor; immunology; hematologic malignancy; myelodysplastic syndrome; adverse drug reaction reporting systems; colorectal tumor; breast tumor; prostate tumor; mesothelioma; chimeric antigen receptor; pleura tumor; kaposi sarcoma; neoplasms, second primary; second cancer; thyroid tumor; adoptive immunotherapy; immunotherapy, adoptive; gastrointestinal tumor; anaplastic large cell lymphoma; acute myeloid leukemia; urinary tract tumor; nervous system tumor; humans; human; male; female; article; tisagenlecleucel t; pharmacovigilance; chimeric antigen receptor t-cell immunotherapy; axicabtagene ciloleucel; lisocabtagene maraleucel; receptors, chimeric antigen; brexucabtagene autoleucel; ciltacabtagene autoleucel; idecabtagene vicleucel; second primary neoplasm
Journal Title:	Blood
Volume:	143
Issue:	20
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2024-05-16
Start Page:	2099
End Page:	2105
Language:	English
DOI:	10.1182/blood.2024024166
PUBMED:	38483155
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190252127&doi=10.1182%2fblood.2024024166&partnerID=40&md5=bb862f7ae7ed20920976b4e4ac327316
Notes:	Article -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/216368